The global orally disintegrating tablet excipient market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The major factors driving the growth of this market are increasing demand for oral medications and growing preference for oral medications over injections or other modes of administration.
Binders had the biggest market share of 37% in 2018. AntPsychotics Drug is the greatest segment of Orally Disintegrating Tablet Excipient application, with a share of 37% in 2018. North America accounted for the largest share in terms of revenue and is expected to continue its dominance throughout the forecast period due to high adoption rates and availability of healthcare facilities across different regions in this region.
- The global population is increasing, which will lead to an increase in the number of people who are diagnosed with chronic diseases.
- The aging population is also a factor that will contribute to the growth of the market for orally disintegrating tablet excipients.
- Increasing awareness about oral health and dental care among consumers will also drive the growth of this market over time.
- The growing demand for convenience products such as tablets and capsules that can be taken without water or food will also fuel this market's growth over time, as these products are easier to consume than traditional pills or capsules that require water or food for consumption, respectively.
- Increasing research and development activities in pharmaceuticals industry is another factor driving this market's growth over time.
Industry Growth Insights published a new data on “Orally Disintegrating Tablet Excipient Market”. The research report is titled “Orally Disintegrating Tablet Excipient Market research by Types (Binders, Glidents, Diluents, Disintegrants, Others, Binders had the biggest market share of 37% in 2018.), By Applications (Anti-Psychotics Drug, Anti-Epileptics Drug, Others, Anti-Epileptics Drug is the greatest segment of Orally Disintegrating Tablet Excipient application, with a share of 37% in 2018.), By Players/Companies BASF, JRS Pharma, Roquette, ABF Ingredients, DFE Pharma, Evonik, Merck KGaA, Ashland, Meggle Pharma, Shin-Etsu, Fuji Chemical Industries, McePharma (Vivesa holding), Cargill Incorporated, Daicel Corporation, Anhui Sunhere Pharmaceutical”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Orally Disintegrating Tablet Excipient Market Research Report
By Type
Binders, Glidents, Diluents, Disintegrants, Others, Binders had the biggest market share of 37% in 2018.
By Application
Anti-Psychotics Drug, Anti-Epileptics Drug, Others, Anti-Epileptics Drug is the greatest segment of Orally Disintegrating Tablet Excipient application, with a share of 37% in 2018.
By Companies
BASF, JRS Pharma, Roquette, ABF Ingredients, DFE Pharma, Evonik, Merck KGaA, Ashland, Meggle Pharma, Shin-Etsu, Fuji Chemical Industries, McePharma (Vivesa holding), Cargill Incorporated, Daicel Corporation, Anhui Sunhere Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
235
Number of Tables & Figures
165
Customization Available
Yes, the report can be customized as per your need.
Global Orally Disintegrating Tablet Excipient Market Report Segments:
The global Orally Disintegrating Tablet Excipient market is segmented on the basis of:
Types
Binders, Glidents, Diluents, Disintegrants, Others, Binders had the biggest market share of 37% in 2018.
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Anti-Psychotics Drug, Anti-Epileptics Drug, Others, Anti-Epileptics Drug is the greatest segment of Orally Disintegrating Tablet Excipient application, with a share of 37% in 2018.
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- BASF
- JRS Pharma
- Roquette
- ABF Ingredients
- DFE Pharma
- Evonik
- Merck KGaA
- Ashland
- Meggle Pharma
- Shin-Etsu
- Fuji Chemical Industries
- McePharma (Vivesa holding)
- Cargill Incorporated
- Daicel Corporation
- Anhui Sunhere Pharmaceutical
Highlights of The Orally Disintegrating Tablet Excipient Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Binders
- Glidents
- Diluents
- Disintegrants
- Others
- Binders had the biggest market share of 37% in 2018.
- By Application:
- Anti-Psychotics Drug
- Anti-Epileptics Drug
- Others
- Anti-Epileptics Drug is the greatest segment of Orally Disintegrating Tablet Excipient application, with a share of 37% in 2018.
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Orally Disintegrating Tablet Excipient Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Orally disintegrating tablet excipient is a type of tablet excipient that dissolves in the mouth. It is used to make tablets that are easy to swallow.
Some of the major players in the orally disintegrating tablet excipient market are BASF, JRS Pharma, Roquette, ABF Ingredients, DFE Pharma, Evonik, Merck KGaA, Ashland, Meggle Pharma, Shin-Etsu, Fuji Chemical Industries, McePharma (Vivesa holding), Cargill Incorporated, Daicel Corporation, Anhui Sunhere Pharmaceutical.
The orally disintegrating tablet excipient market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Orally Disintegrating Tablet Excipient Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Orally Disintegrating Tablet Excipient Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Orally Disintegrating Tablet Excipient Market - Supply Chain
4.5. Global Orally Disintegrating Tablet Excipient Market Forecast
4.5.1. Orally Disintegrating Tablet Excipient Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Orally Disintegrating Tablet Excipient Market Size (000 Units) and Y-o-Y Growth
4.5.3. Orally Disintegrating Tablet Excipient Market Absolute $ Opportunity
5. Global Orally Disintegrating Tablet Excipient Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Orally Disintegrating Tablet Excipient Market Size and Volume Forecast by Type
5.3.1. Binders
5.3.2. Glidents
5.3.3. Diluents
5.3.4. Disintegrants
5.3.5. Others
5.3.6. Binders had the biggest market share of 37% in 2018.
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Orally Disintegrating Tablet Excipient Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Orally Disintegrating Tablet Excipient Market Size and Volume Forecast by Application
6.3.1. Anti-Psychotics Drug
6.3.2. Anti-Epileptics Drug
6.3.3. Others
6.3.4. Anti-Epileptics Drug is the greatest segment of Orally Disintegrating Tablet Excipient application, with a share of 37% in 2018.
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Orally Disintegrating Tablet Excipient Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Orally Disintegrating Tablet Excipient Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Orally Disintegrating Tablet Excipient Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Orally Disintegrating Tablet Excipient Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Orally Disintegrating Tablet Excipient Demand Share Forecast, 2019-2026
9. North America Orally Disintegrating Tablet Excipient Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Orally Disintegrating Tablet Excipient Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Orally Disintegrating Tablet Excipient Market Size and Volume Forecast by Application
9.4.1. Anti-Psychotics Drug
9.4.2. Anti-Epileptics Drug
9.4.3. Others
9.4.4. Anti-Epileptics Drug is the greatest segment of Orally Disintegrating Tablet Excipient application, with a share of 37% in 2018.
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Orally Disintegrating Tablet Excipient Market Size and Volume Forecast by Type
9.7.1. Binders
9.7.2. Glidents
9.7.3. Diluents
9.7.4. Disintegrants
9.7.5. Others
9.7.6. Binders had the biggest market share of 37% in 2018.
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Orally Disintegrating Tablet Excipient Demand Share Forecast, 2019-2026
10. Latin America Orally Disintegrating Tablet Excipient Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Orally Disintegrating Tablet Excipient Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Orally Disintegrating Tablet Excipient Market Size and Volume Forecast by Application
10.4.1. Anti-Psychotics Drug
10.4.2. Anti-Epileptics Drug
10.4.3. Others
10.4.4. Anti-Epileptics Drug is the greatest segment of Orally Disintegrating Tablet Excipient application, with a share of 37% in 2018.
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Orally Disintegrating Tablet Excipient Market Size and Volume Forecast by Type
10.7.1. Binders
10.7.2. Glidents
10.7.3. Diluents
10.7.4. Disintegrants
10.7.5. Others
10.7.6. Binders had the biggest market share of 37% in 2018.
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Orally Disintegrating Tablet Excipient Demand Share Forecast, 2019-2026
11. Europe Orally Disintegrating Tablet Excipient Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Orally Disintegrating Tablet Excipient Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Orally Disintegrating Tablet Excipient Market Size and Volume Forecast by Application
11.4.1. Anti-Psychotics Drug
11.4.2. Anti-Epileptics Drug
11.4.3. Others
11.4.4. Anti-Epileptics Drug is the greatest segment of Orally Disintegrating Tablet Excipient application, with a share of 37% in 2018.
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Orally Disintegrating Tablet Excipient Market Size and Volume Forecast by Type
11.7.1. Binders
11.7.2. Glidents
11.7.3. Diluents
11.7.4. Disintegrants
11.7.5. Others
11.7.6. Binders had the biggest market share of 37% in 2018.
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Orally Disintegrating Tablet Excipient Demand Share, 2019-2026
12. Asia Pacific Orally Disintegrating Tablet Excipient Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Orally Disintegrating Tablet Excipient Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Orally Disintegrating Tablet Excipient Market Size and Volume Forecast by Application
12.4.1. Anti-Psychotics Drug
12.4.2. Anti-Epileptics Drug
12.4.3. Others
12.4.4. Anti-Epileptics Drug is the greatest segment of Orally Disintegrating Tablet Excipient application, with a share of 37% in 2018.
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Orally Disintegrating Tablet Excipient Market Size and Volume Forecast by Type
12.7.1. Binders
12.7.2. Glidents
12.7.3. Diluents
12.7.4. Disintegrants
12.7.5. Others
12.7.6. Binders had the biggest market share of 37% in 2018.
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Orally Disintegrating Tablet Excipient Demand Share, 2019-2026
13. Middle East & Africa Orally Disintegrating Tablet Excipient Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Orally Disintegrating Tablet Excipient Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Orally Disintegrating Tablet Excipient Market Size and Volume Forecast by Application
13.4.1. Anti-Psychotics Drug
13.4.2. Anti-Epileptics Drug
13.4.3. Others
13.4.4. Anti-Epileptics Drug is the greatest segment of Orally Disintegrating Tablet Excipient application, with a share of 37% in 2018.
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Orally Disintegrating Tablet Excipient Market Size and Volume Forecast by Type
13.7.1. Binders
13.7.2. Glidents
13.7.3. Diluents
13.7.4. Disintegrants
13.7.5. Others
13.7.6. Binders had the biggest market share of 37% in 2018.
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Orally Disintegrating Tablet Excipient Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Orally Disintegrating Tablet Excipient Market: Market Share Analysis
14.2. Orally Disintegrating Tablet Excipient Distributors and Customers
14.3. Orally Disintegrating Tablet Excipient Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. BASF
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. JRS Pharma
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Roquette
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. ABF Ingredients
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. DFE Pharma
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Evonik
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Merck KGaA
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Ashland
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Meggle Pharma
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Shin-Etsu
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Fuji Chemical Industries
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. McePharma (Vivesa holding)
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Cargill Incorporated
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Daicel Corporation
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Anhui Sunhere Pharmaceutical
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
